Following the announcement that the FDA had accepted tovorafenib’s NDA filing with priority review, Oppenheimer called the news “a big win” for Day One Biopharmaceuticals and the decision to proceed without an advisory committee “the proverbial cherry on top of the cake.” However, the firm still views upside to shares as constrained by the market opportunity as it projects peak sales of $350M. Oppenheimer reiterates a Perform rating on Day One shares with no price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One announces FDA acceptance of NDA, priority review for tovorafenib
- Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
- Fly Insider: Tango Therapeutics, VMware among week’s notable insider trades
- Avadel Pharmaceuticals added to Conviction List at Needham
- Day One Biopharmaceuticals files automatic mixed securities shelf
